Achilles Therapeutics plc (ACHL)
| Market Cap | 475.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 40.62M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 17 |
| Last Price | $11.72 |
| Previous Close | $11.92 |
| Change ($) | -0.21 |
| Change (%) | -1.72% |
| Day's Open | 11.83 |
| Day's Range | 11.72 - 12.41 |
| Day's Volume | 2,462 |
| 52-Week Range | 11.42 - 18.95 |
- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -
LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced...
LONDON, United Kingdom, May 03, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors,...
LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today present...
LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...
Achilles Therapeutics plc (NASDAQ: ACHL) announced the pricing of its IPO on the Nasdaq that will raise US$175.5mln (£127.8mln). The clinical-stage biopharma, which is developing precision T cell therap...
LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...
Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
Achilles Therapeutics plc has filed to go public with an IPO on the NASDAQ.
About ACHL
Achilles Therapeutics is a clinical stage immuno-oncology biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumors. Our platform enables us to identify mutations formed early in the development of a cancer that give rise to antigens. We refer to this novel class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, we have developed a proprietary bioinformatic platform called PELEUS. This platform employs sophisticated statistical algorithms trained on the uniqu... [Read more...]
| Industry Biotechnology | IPO Date Mar 31, 2021 |
| CEO Iraj Ali, Ph.D. | Employees 153 |
| Stock Exchange NASDAQ | Ticker Symbol ACHL |